VALSOURCE

GLP-1 Manufacturing Challenges and Opportunities

Demand Boom & Supply Constraints

GLP-1 receptor agonists, such as semaglutide (e.g. Ozempic, Wegovy) and tirzepatide (e.g. Mounjaro, Zepbound), have surged in global demand due to their effectiveness in treating type 2 diabetes and obesity. The growing popularity of these drugs has led financial analysts to predict that the GLP-1 market will exceed $100 billion by 2030. Approximately 30 million people in the U.S. are projected to use GLP-1s by 2030, which equates to about 9% of its population.

Despite the increasing demand for GLP-1 drugs, production still lags far behind. Globally, manufacturing capacity fulfills only 40-50% of the current prescriptions. With the rising global obesity epidemic and the increasing need for effective weight-loss treatments, the pharmaceutical industry is facing mounting pressure to revolutionize faster and more efficient GLP-1 manufacturing in the face of several challenges.

Complex Production & Fragile Supply Chains

To meet this demand surge, manufacturers are scaling up rapidly. GLP-1 drugs must abide by stringent regulatory standards, including Good Manufacturing Practices (GMP), which further increase the complexity and cost of these production processes as continuous monitoring, documentation, and validation of the processes are required.

When manufactured using biologic cell culture processes, GLP-1s require 15–20 intricate steps, including microbial fermentation and multi-stage purification. These complex processes are often prone to error, any of which may jeopardize product release and further exacerbate supply shortages. In addition, GLP-1s often use materials sourced from locations vulnerable to supply disruption. Events like the 2022 Shanghai lockdowns can lead to production delays.

Injectable forms of GLP-1s are subject to increased regulatory scrutiny based on the aseptic manufacturing requirements necessary to ensure the products are rendered sterile. Manufacturers must perform rigorous risk assessments to develop comprehensive contamination control strategies, requiring in-depth knowledge of both microbiology and quality risk management.

Cold-chain logistics are equally vulnerable. These injectables require 2–8 °C storage from production to patient delivery. In emerging markets, mishandling ruins up to 20% of shipments, forcing manufacturers to overproduce by about 25% to meet demand while compensating for anticipated product loss over the distribution chain.

ValSource experts can help with all aspects of the manufacturing process, including equipment and material purchasing, validation and qualification, equipment and instrument calibration, process engineering and manufacturing science support, microbiology and contamination control expertise, and quality risk management planning and facilitation.

(Continued)

Emerging Trends & Disruptors

Oral GLP-1 Therapies

The development of oral-dose small-molecule GLP-1 agonists has the potential to disrupt the current market share for existing GLP-1 therapies. A few new drugs have just finished Phase III trials with positive outcomes, demonstrating diabetes control and weight loss comparable to injectables without serious side effects. GLP-1 production through peptide synthesis (as opposed to cell culture) and the transition from sterile injectable to oral dose are likely to result in a significant reduction in the cost of goods, which could ease some of the manufacturing complexity and lead to more affordability for consumers.

Advanced Manufacturing Technology

Biopharma is increasingly deploying digital twins and AI-driven manufacturing. Platforms now simulate processes in real time to optimize quality and expedite scale-up. Self-driving “tableting factories” can design and produce new tablets within hours, greatly accelerating product development.

Growing Competition & Biosimilars

Although two pharmaceutical companies currently dominate in GLP-1s (representing over 85% market share), other companies are entering the GLP-1 space and increasing competition. Biosimilars of semaglutide are expected to enter markets like Canada (2026) and Brazil (2026), while 503(b) compounding pharmacies remain ready to address demand concerns in the event of further shortages. This will intensify competition, pressure prices, and transform distribution models—with multichannel strategies and direct-to-consumer e-pharmacy options emerging.

Conclusion

The GLP-1 manufacturing ecosystem remains in expansion mode—racing to close a supply gap that will likely persist until 2026. Meanwhile, groundbreaking oral alternatives and next-generation technologies promise to reshape production and access. By 2030, this class of medications will become more mainstream, globally available, and diversified in delivery formats—though pricing pressures and regulatory policies will inevitably temper profit margins. The next five years will determine whether GLP-1 therapies evolve from a niche medical marvel to a sustainable, affordable staple of global health.

Kelly Waldron, PhD
Business Unit Manager
kwaldron@valsource.com | 508.380.0243